| Year |
Citation |
Score |
| 2024 |
Kordower J, Butler D, Chatterjee D, D'Brant L, Hiller B, Marmion D, Sandoval I, Luk K, Manfredsson F, Messer A. Engineered Nanobodies With Programmable Target Antigen Proteolysis (Ptap) Fusions Regulate Intracellular Alpha-synuclein in Vitro and in Vivo. Research Square. PMID 38585932 DOI: 10.21203/rs.3.rs-4088206/v1 |
0.68 |
|
| 2021 |
Chatterjee D, Marmion DJ, McBride JL, Manfredsson FP, Butler D, Messer A, Kordower JH. Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Therapy. PMID 33753910 DOI: 10.1038/s41434-021-00244-y |
0.663 |
|
| 2019 |
Messer A, Butler DC. Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders. Neurobiology of Disease. 104619. PMID 31669671 DOI: 10.1016/j.nbd.2019.104619 |
0.358 |
|
| 2018 |
Chatterjee D, Bhatt M, Butler D, De Genst E, Dobson CM, Messer A, Kordower JH. Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model. Npj Parkinson's Disease. 4: 25. PMID 30155513 DOI: 10.1038/S41531-018-0062-4 |
0.681 |
|
| 2018 |
Ramsingh AI, Gray SJ, Reilly A, Koday M, Bratt D, Koday MT, Murnane R, Smedley J, Hu Y, Messer A, Fuller DH. Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation. Plos One. 13: e0198154. PMID 29874260 DOI: 10.1371/Journal.Pone.0198154 |
0.342 |
|
| 2016 |
Butler DC, Joshi SN, Genst E, Baghel AS, Dobson CM, Messer A. Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ. Plos One. 11: e0165964. PMID 27824888 DOI: 10.1371/Journal.Pone.0165964 |
0.603 |
|
| 2014 |
Messer A. Engineered antibody therapies coming of age for aging brains. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1725-7. PMID 25269943 DOI: 10.1038/Mt.2014.170 |
0.493 |
|
| 2014 |
Messer A, Manley K, Lemere CA. Immunotherapeutics for Neurological Disorders Handbook of Therapeutic Antibodies: Second Edition. 2: 1215-1230. DOI: 10.1002/9783527682423.ch40 |
0.345 |
|
| 2013 |
Bhatt MA, Messer A, Kordower JH. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. Journal of Parkinson's Disease. 3: 581-91. PMID 24270241 DOI: 10.3233/Jpd-130252 |
0.544 |
|
| 2013 |
Messer A, Joshi SN. Intrabodies as neuroprotective therapeutics. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 10: 447-58. PMID 23649691 DOI: 10.1007/S13311-013-0193-6 |
0.626 |
|
| 2013 |
Tomé S, Manley K, Simard JP, Clark GW, Slean MM, Swami M, Shelbourne PF, Tillier ER, Monckton DG, Messer A, Pearson CE. MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice. Plos Genetics. 9: e1003280. PMID 23468640 DOI: 10.1371/Journal.Pgen.1003280 |
0.417 |
|
| 2012 |
Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. Mabs. 4: 686-93. PMID 22929188 DOI: 10.4161/Mabs.21696 |
0.606 |
|
| 2012 |
Butler DC, McLear JA, Messer A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Progress in Neurobiology. 97: 190-204. PMID 22120646 DOI: 10.1016/J.Pneurobio.2011.11.004 |
0.458 |
|
| 2011 |
Butler DC, Messer A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. Plos One. 6: e29199. PMID 22216210 DOI: 10.1371/Journal.Pone.0029199 |
0.456 |
|
| 2011 |
Hathorn T, Snyder-Keller A, Messer A. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease. Neurobiology of Disease. 41: 43-50. PMID 20736066 DOI: 10.1016/J.Nbd.2010.08.017 |
0.718 |
|
| 2010 |
Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. Journal of Neuropathology and Experimental Neurology. 69: 1078-85. PMID 20838238 DOI: 10.1097/Nen.0B013E3181F530Ec |
0.73 |
|
| 2010 |
Bortvedt SF, McLear JA, Messer A, Ahern-Rindell AJ, Wolfgang WJ. Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease Neurobiology of Disease. 40: 130-134. PMID 20399860 DOI: 10.1016/J.Nbd.2010.04.007 |
0.479 |
|
| 2010 |
Kvam E, Sierks MR, Shoemaker CB, Messer A. Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Engineering, Design & Selection : Peds. 23: 489-98. PMID 20378699 DOI: 10.1093/Protein/Gzq022 |
0.377 |
|
| 2009 |
Messer A, Lynch SM, Butler DC. Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opinion On Biological Therapy. 9: 1189-97. PMID 19653865 DOI: 10.1517/14712590903176387 |
0.474 |
|
| 2009 |
Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. Plos One. 4: e5727. PMID 19492089 DOI: 10.1371/Journal.Pone.0005727 |
0.429 |
|
| 2008 |
Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. Journal of Molecular Biology. 377: 136-47. PMID 18237741 DOI: 10.1016/J.Jmb.2007.11.096 |
0.417 |
|
| 2008 |
McLear JA, Lebrecht D, Messer A, Wolfgang WJ. Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 2003-11. PMID 18199697 DOI: 10.1096/fj.07-099689 |
0.308 |
|
| 2007 |
Goryunov D, Adebola A, Jefferson JJ, Leung CL, Messer A, Liem RK. Molecular characterization of the genetic lesion in Dystonia musculorum (dt-Alb) mice. Brain Research. 1140: 179-87. PMID 16725123 DOI: 10.1016/J.Brainres.2006.04.068 |
0.39 |
|
| 2006 |
Messer A, McLear J. The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 20: 327-33. PMID 17176119 DOI: 10.2165/00063030-200620060-00002 |
0.432 |
|
| 2006 |
McLear J, Webster J, Webster N, Messer A. 249. Fusion Intrabodies as Anti-Huntington Gene Therapy Molecular Therapy. 13: S95-S96. DOI: 10.1016/J.Ymthe.2006.08.276 |
0.414 |
|
| 2006 |
Miller TW, Messer A. Gene Therapy for CNS Diseases Using Intrabodies Gene Therapy of the Central Nervous System: From Bench to Bedside. 133-149. DOI: 10.1016/B978-012397632-1/50012-5 |
0.33 |
|
| 2005 |
Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proceedings of the National Academy of Sciences of the United States of America. 102: 11563-8. PMID 16061794 DOI: 10.1073/Pnas.0505321102 |
0.492 |
|
| 2005 |
Miller TW, Messer A. Intrabody applications in neurological disorders: progress and future prospects. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 394-401. PMID 15964243 DOI: 10.1016/J.Ymthe.2005.04.003 |
0.442 |
|
| 2005 |
Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiology of Disease. 19: 47-56. PMID 15837560 DOI: 10.1016/J.Nbd.2004.11.003 |
0.435 |
|
| 2005 |
Zhou C, Messer A. 943. Anti-alpha-Synuclein scFv Study Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.486 |
0.419 |
|
| 2004 |
Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, Messer A, Lindquist S, Ingram VM, Wittrup KD. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proceedings of the National Academy of Sciences of the United States of America. 101: 17616-21. PMID 15598740 DOI: 10.1073/Pnas.0408134101 |
0.46 |
|
| 2004 |
Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1023-31. PMID 15564134 DOI: 10.1016/J.Ymthe.2004.08.019 |
0.319 |
|
| 2004 |
Shirley LT, Messer A. Early postnatal Purkinje cells from staggerer mice undergo aberrant development in vitro with characteristic morphologic and gene expression abnormalities. Brain Research. Developmental Brain Research. 152: 153-7. PMID 15351503 DOI: 10.1016/J.Devbrainres.2004.06.010 |
0.368 |
|
| 2004 |
Colby DW, Garg P, Holden T, Chao G, Webster JM, Messer A, Ingram VM, Wittrup KD. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. Journal of Molecular Biology. 342: 901-12. PMID 15342245 DOI: 10.1016/J.Jmb.2004.07.054 |
0.351 |
|
| 2004 |
Bolivar VJ, Manley K, Messer A. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice. Brain Research. 1005: 29-35. PMID 15044061 DOI: 10.1016/J.Brainres.2004.01.021 |
0.342 |
|
| 2004 |
Murphy RC, Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Research. Molecular Brain Research. 121: 141-5. PMID 14969746 DOI: 10.1016/J.Molbrainres.2003.11.011 |
0.446 |
|
| 2004 |
Miller TW, Wolfgang WJ, Manley K, Zhou Y, Zhou C, Webster JM, Mazarakis ND, Messer A. 48. In vivo and in situ delivery of huntingtin-specific single-chain Fv intrabody genes as therapeutic agents for Huntington's disease|[ast]| Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.071 |
0.473 |
|
| 2003 |
Bolivar VJ, Manley K, Messer A. Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behavioral Neuroscience. 117: 1233-42. PMID 14674843 DOI: 10.1037/0735-7044.117.6.1233 |
0.375 |
|
| 2003 |
Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 572-9. PMID 12718899 DOI: 10.1016/S1525-0016(03)00063-7 |
0.316 |
|
| 2002 |
Bolivar VJ, Scott Ganus J, Messer A. The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse. Brain Research. 937: 74-82. PMID 12020865 DOI: 10.1016/S0006-8993(02)02470-8 |
0.379 |
|
| 2001 |
Chu-LaGraff Q, Kang X, Messer A. Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice. Brain Research Bulletin. 56: 307-12. PMID 11719265 DOI: 10.1016/S0361-9230(01)00598-6 |
0.409 |
|
| 2001 |
Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 98: 4764-9. PMID 11296304 DOI: 10.1073/Pnas.071058398 |
0.489 |
|
| 2001 |
Murphy RC, Messer A. Gene transfer methods for CNS organotypic cultures: A comparison of three nonviral methods Molecular Therapy. 3: 113-121. PMID 11162318 DOI: 10.1006/Mthe.2000.0235 |
0.313 |
|
| 2000 |
Messer A, Kang X. Control of transcription in the RORa-staggerer mutant mouse cerebellum: Glutamate receptor delta2 mRNA International Journal of Developmental Neuroscience. 18: 663-668. PMID 10978844 DOI: 10.1016/S0736-5748(00)00038-1 |
0.308 |
|
| 2000 |
Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A, Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proceedings of the National Academy of Sciences of the United States of America. 97: 6809-14. PMID 10829080 DOI: 10.1073/Pnas.120166397 |
0.357 |
|
| 1999 |
Manley K, Shirley TL, Flaherty L, Messer A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nature Genetics. 23: 471-3. PMID 10581038 DOI: 10.1038/70598 |
0.432 |
|
| 1999 |
Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E, Messer A, Sharp J, Wheeler R, Kusumi K, Mole S, Liu W, Soares MB, Bonaldo MDF, Hirvasniemi A, De La Chapelle A, et al. The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8 Nature Genetics. 23: 233-236. PMID 10508524 DOI: 10.1038/13868 |
0.377 |
|
| 1999 |
Manley K, Pugh J, Messer A. Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice Brain Research. 835: 74-79. PMID 10448198 DOI: 10.1016/S0006-8993(99)01451-1 |
0.38 |
|
| 1999 |
Messer A, Manley K, Plummer JA. An early-onset congenic strain of the motor neuron degeneration (rand) mouse Molecular Genetics and Metabolism. 66: 393-397. PMID 10191135 DOI: 10.1006/Mgme.1999.2817 |
0.382 |
|
| 1999 |
Cooper JD, Messer A, Feng AK, Chua-Couzens J, Mobley WC. Apparent loss and hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for partial response to insulin-like growth factor-1 treatment. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 2556-67. PMID 10087069 DOI: 10.1523/Jneurosci.19-07-02556.1999 |
0.381 |
|
| 1998 |
Dalpé G, Leclerc N, Vallée A, Messer A, Mathieu M, De Repentigny Y, Kothary R. Dystonin Is Essential for Maintaining Neuronal Cytoskeleton Organization. Molecular and Cellular Neurosciences. 10: 243-57. PMID 9618216 DOI: 10.1006/Mcne.1997.0660 |
0.347 |
|
| 1998 |
Li J, Nixon R, Messer A, Berman S, Bursztajn S. Altered gene expression for calpain/calpastatin system in motor neuron degeneration (Mnd) mutant mouse brain and spinal cord Molecular Brain Research. 53: 174-186. PMID 9473662 DOI: 10.1016/S0169-328X(97)00295-7 |
0.358 |
|
| 1997 |
Porter JC, Messer A, Peterson A. The motor neuron degeneration (mnd) gene acts intrinsically in motor neurons and peripheral fibroblasts Molecular and Cellular Neurosciences. 9: 185-193. PMID 9245501 DOI: 10.1006/Mcne.1997.0617 |
0.399 |
|
| 1995 |
Plummer J, Peterson A, Messer A. Accelerated and widespread neuronal loss occurs in motor neuron degeneration (mnd) mice expressing a neurofilament-disrupting transgene Molecular and Cellular Neurosciences. 6: 532-543. PMID 8742270 DOI: 10.1006/Mcne.1995.0005 |
0.419 |
|
| 1995 |
Messer A, Plummer J, MacMillen MC, Frankel WN. Genetics of primary and timing effects in the mnd mouse American Journal of Medical Genetics. 57: 361-364. PMID 7668363 DOI: 10.1002/Ajmg.1320570251 |
0.412 |
|
| 1994 |
Messer A. Mutant mouse models of ALS Neurobiology of Aging. 15: 247-248. PMID 7838302 DOI: 10.1016/0197-4580(94)90123-6 |
0.439 |
|
| 1993 |
Messer A, Plummer J. Accumulating autofluorescent material as a marker for early changes in the spinal cord of the Mnd mouse Neuromuscular Disorders. 3: 129-134. PMID 8358238 DOI: 10.1016/0960-8966(93)90004-4 |
0.368 |
|
| 1992 |
Messer A, Plummer J, Maskin P, Coffin JM, Frankel WN. Mapping of the motor neuron degeneration (Mnd) gene, a mouse model of amyotrophic lateral sclerosis (ALS) Genomics. 13: 797-802. PMID 1639406 DOI: 10.1016/0888-7543(92)90155-L |
0.397 |
|
| 1991 |
Messer A, Eisenberg B, Plummer J. The Lurcher cerebellar mutant phenotype is not expressed on a staggerer mutant background Journal of Neuroscience. 11: 2295-2302. PMID 1869916 DOI: 10.1523/Jneurosci.11-08-02295.1991 |
0.375 |
|
| 1990 |
Messer A, Plummer-Siegard J, Eisenberg B. Staggerer mutant mouse Purkinje cells do not contain detectable calmodulin mRNA Journal of Neurochemistry. 55: 293-302. PMID 2355223 DOI: 10.1111/J.1471-4159.1990.Tb08851.X |
0.313 |
|
| 1989 |
Messer A, Eisenberg B, Martin DL. Effects of mild hyperthyroidism on levels of amino acids in the developing lurcher cerebellum Journal of Neurogenetics. 5: 77-85. PMID 2703942 DOI: 10.3109/01677068909167266 |
0.332 |
|
| 1988 |
Messer A. Thyroxine injections do not cause premature induction of thymidine kinase in sg/sg mice Journal of Neurochemistry. 51: 888-891. PMID 3411329 DOI: 10.1111/J.1471-4159.1988.Tb01825.X |
0.318 |
|
| 1987 |
Messer A, Strominger NL, Mazurkiewicz JE. Histopathology of the late-onset motor neuron degeneration (mnd) mutant in the mouse Journal of Neurogenetics. 4: 201-213. PMID 3612378 DOI: 10.3109/01677068709167181 |
0.355 |
|
| 1986 |
Messer A, Flaherty L. Autosomal dominance in a late-onset motor neuron disease in the mouse. Journal of Neurogenetics. 3: 345-55. PMID 3783318 DOI: 10.3109/01677068609106858 |
0.402 |
|
| 1985 |
Messer A, Snodgrass GL, Maskin P. Timecourse of effects of triiodothyronine on mouse cerebellar cells cultured by two different methods International Journal of Developmental Neuroscience. 3: 291-299. DOI: 10.1016/0736-5748(85)90034-6 |
0.342 |
|
| 1984 |
Messer A, Hatch K. Persistence of cerebellar thymidine kinase in staggerer and hypothyroid mutants Journal of Neurogenetics. 1: 239-248. PMID 6536728 DOI: 10.3109/01677068409107089 |
0.322 |
|
| 1984 |
Messer A, Snodgrass GL, Maskin P. Enhanced survival of cultured cerebellar Purkinje cells by plating on antibody to Thy-1 Cellular and Molecular Neurobiology. 4: 285-290. PMID 6395956 DOI: 10.1007/Bf00733591 |
0.327 |
|
| 1984 |
Messer A, Maskin P, Snodgrass GL. Effects of triiodothyronine (T3) on the development of rat cerebellar cells in culture International Journal of Developmental Neuroscience. 2. DOI: 10.1016/0736-5748(84)90022-4 |
0.327 |
|
| 1983 |
Messer A, Jennings R, Maskin P. Low concentrations of trifluoperazine affect striatal cells in culture Journal of Neurochemistry. 41: 903-908. PMID 6619857 DOI: 10.1111/J.1471-4159.1983.Tb09033.X |
0.302 |
|
| 1981 |
Messer A, Mazurkiewicz JE, Maskin P. Growth of dissociated rat cerebellar cells using serum-free supplemented media and varied transferrin concentrations Cellular and Molecular Neurobiology. 1: 99-114. PMID 7346166 DOI: 10.1007/Bf00736042 |
0.314 |
|
| 1981 |
Messer A. Primary monolayer cultures of the rat corpus striatum: Morphology and properties related to acetylcholine and γ-aminobutyrate Neuroscience. 6: 2677-2687. PMID 7322357 DOI: 10.1016/0306-4522(81)90112-3 |
0.337 |
|
| 1980 |
Messer A, Strominger NL. An allele of the mouse mutant dystonia musculorum exhibits lesions in red nucleus and striatum Neuroscience. 5: 543-549. PMID 7374955 DOI: 10.1016/0306-4522(80)90051-2 |
0.372 |
|
| 1980 |
Messer A, Maskin P. Short-term effects of kainic acid on rat cerebellar cells in monolayer cultures Neuroscience Letters. 19: 173-177. PMID 7052526 DOI: 10.1016/0304-3940(80)90190-1 |
0.305 |
|
| 1980 |
Messer A. Cerebellar Granule Cells in Normal and Neurological Mutants of Mice Advances in Cell Biology. 1: 179-207. DOI: 10.1016/B978-0-12-008301-5.50009-1 |
0.368 |
|
| 1978 |
Hatten ME, Messer A. Postnatal cerebellar cells from staggerer mutant mice express embryonic cell surface characteristic [19] Nature. 276: 504-506. PMID 723931 DOI: 10.1038/276504A0 |
0.317 |
|
| 1978 |
Messer A. Abnormal staggerer cerebellar cell interactions and survival in vitro Neuroscience Letters. 9: 185-188. DOI: 10.1016/0304-3940(78)90069-1 |
0.303 |
|
| 1977 |
Messer A, Smith DM. In vitro behavior of granule cells from staggerer and weaver mutants of mice Brain Research. 130: 13-23. PMID 328112 DOI: 10.1016/0006-8993(77)90839-3 |
0.339 |
|
| 1977 |
Messer A. The maintenance and identification of mouse cerebellar granule cells in monolayer culture Brain Research. 130: 1-12. PMID 328111 DOI: 10.1016/0006-8993(77)90838-1 |
0.306 |
|
| Show low-probability matches. |